ARCHIVES

IDMC Recommends Halting Phase III Trial Of Onartuzumab in MET-Positive NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

Supporters And A Critic Of Burzynski Comment

October 30, 1998

DCBD Board Approves Recompetition Concepts, Including Cell Banks, Contrast Agents, Hepatoma Resources

November 14, 1980

NCI Plans Program To Help Academics With Initial Stages of Drug Discovery.

November 30, 2007

Lawyer Says Salick didn’t Anticipate Ouster By Zeneza

May 2, 1997

Regular Exercise May Prevent Cancer, Improve Survival

April 30, 2004

Ellence Has Lower Risk Of Heart Damage, Study Finds

August 27, 2004